The Pharmacy Times® Digestive Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health of the digestive system, including Crohn disease, inflammatory bowel disease, irritable bowel syndrome, and ulcerative colitis.
April 15th 2024
There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Improving Knowledge, Access, and Utilization of Biosimilars for Inflammatory Bowel Disease
1.0 Credit / Gastroenterology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
1.0 Credit / Gastroenterology
View More
The Evolving Treatment Landscape of Acid-Related Disorders: The Role of New and Emerging Potassium-Competitive Acid Blocker Therapies (Pharmacist Credit)
2.0 Credits / H Pylori
View More
The Evolving Treatment Landscape of Acid-Related Disorders: The Role of New and Emerging Potassium-Competitive Acid Blocker Therapies (Pharmacy Technician Credit)
2.0 Credits / H Pylori
View More
Integrating Biologic Therapy Into Clinical Practice for the Management of Eosinophilic Esophagitis
1.5 Credits / Gastroenterology, Immunology
View More
Clinical Management of Short Bowel Syndrome: Pharmacist-Led Strategies in Patient Care
1.5 Credits / Gastroenterology
View More
Understanding the Burden of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
Emerging Biologic Therapy for the Management of Eosinophilic Esophagitis in Children
1.0 Credit / Gastroenterology, Immunology
View More
The Expertise of the Specialty Pharmacist in Pediatric Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Optimizing Inflammatory Bowel Disease Treatment: A Pharmacist's Guide to Biologics and Monoclonal Antibodies
1.0 Credits / Gastroenterology, Immunology
View More
Daily Medication Pearl: Upadacitinib (Rinvoq)
March 4th 2022Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
Read More